MedTrace Logo

Establish a Non-invasive Prenatal Genotyping and Extraction Technology to Diagnose and Treat the HDN.

NCT02969174 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2016-11-21

No results posted yet for this study

Summary

To establish a genotyping and extraction technology of non invasive prenatal diagnosis for fetal blood group genotype from cell-free fetal DNA in peripheral blood of pregnant women.

To achieve prenatal accurate identification of fetal blood group genotypes，and provide credible theoretical evidence for the prenatal diagnosis and treatment of hemolytic disease of newborn (HDN).

Conditions

  • HDFN

Interventions

OTHER

zimin Lu,Guo Sa

chengzhong Liu

Sponsors & Collaborators

  • Shanghai Tongji Hospital, Tongji University School of Medicine

    lead OTHER

Eligibility

Min Age
12 Weeks
Max Age
38 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02969174 on ClinicalTrials.gov